Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Clinical Trial

Official title:

Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05755087
• Other study ID #: OSU-21359
• Secondary ID: NCI-2023-00200
• Status: Recruiting
• Phase: Phase 1
• Start date: March 6, 2023
• Est. completion date: March 5, 2027

Study information

• Verified date: December 2023
• Source: Ohio State University Comprehensive Cancer Center
• Contact: The Ohio State Comprehensive Cancer Center
• Phone: 800-293-5066
• Email: OSUCCCClinicaltrials[@]osumc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.

Description:

PRIMARY OBJECTIVES:

I. To determine the safety and tolerability of tegavivint in patients with relapsed/refractory c-Myc overexpressing large B-cell lymphoma.

II. To determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of tegavivint.

SECONDARY OBJECTIVES:

I. To determine the preliminary efficacy of tegavivint in patients with relapsed/refractory c-Myc overexpressing large B-cell lymphoma.

II. To determine the pharmacokinetic parameters of tegavivint.

EXPLORATORY OBJECTIVES:

I. To correlate response to tegavivint with the presence of MYC, FBW7 and SKP2 mutations.

II. To correlate response to tegavivint with TBL1 and c-Myc expression assessed by standard IHC on archived tumor biopsy.

III. To determine the effects of tegavivint on immune cell subsets viability and function.

OUTLINE: This is a dose-escalation study of tegavivint.

Patients receive tegavivint intravenously (IV) on study. Patients also undergo computed tomography (CT) and/or positron emission tomography (PET) and undergo blood sample collection throughout the trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: March 5, 2027
• Est. primary completion date: March 5, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

One of the following three conditions:

• Relapsed/refractory histologically confirmed germinal center B-cell-like (GCB) and non-GCB diffuse large B cell lymphoma (DLBCL) with the following features:

• Increased expression of MYC (>= 40%) and BCL2 (>= 50%) by immunohistochemistry (IHC) or

• Presence of isolated MYC translocation Or

• Relapsed/refractory histologically confirmed high-grade B-cell lymphoma (HGBCL) (double hit [DH] and triple hit [TH]) with translocations of MYC and BCL2 and/or BCL6 Or

• Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL

• Presence of BCL2 translocation with increased expression of MYC (=40%) with or without MYC translocation

• Patients must have had at least two prior systemic therapies

• Patients must be ineligible for or refused autologous or allogenic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy. Prior autologous stem cell transplant and/or CAR-T are allowed, if received >= 3 months prior to enrollment

• Age >= 18 years

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

• Patients must have radiographically measurable disease by standard positron emission tomography (PET) uptake with at least one site of measured disease by standardized uptake value (SUV)

• Absolute neutrophil count (ANC) > 1,000/mcL

• Platelet count > 75,000/mcL

• Total bilirubin =< 1.5 x the upper limit of the normal range (ULN)

• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x institutional ULN

• Creatinine clearance >= 60 ml/min by Cockcroft-Gault (actual body weight will be used to estimate creatinine clearance)

• Patients must be willing and able to understand and give written informed consent and comply with all study related procedures

• Women of child-bearing potential (WOCBP) and men who are sexually active with WOCBP must agree to use one hormonal contraceptive (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation; and one effective method of contraception, including male condom, female condom, cervical cap, diaphragm or contraceptive sponge or abstain from sex for the duration of study participation and for 4 months following completion of tegavivint administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

Contraception includes:

• Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception

• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment

• Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient

• Use of oral (estrogen and progesterone), injected or implanted combined hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception

• Sexually active males must use a condom during intercourse while taking drug and for 4 months after stopping study treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential

Exclusion Criteria:

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to tegavivint or other agents used in study

• Known active central nervous system (CNS) lymphoma, history of CNS involvement allowed if in remission for >= 3 months

• Evidence of chronic active Hepatitis B, chronic active Hepatitis C infection

• Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy (e.g., strong CYP3A inhibitors and/or concomitant medications that are excluded) are ineligible because of the potential for pharmacokinetic interactions with tegavivint

• Known history of active TB (Bacillus Tuberculosis)

• Major surgery within 3 weeks prior to start of study treatment

• Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality or corrected QT interval (QTc) > 480 msec

• Uncontrolled concurrent illness including, but not limited to: ongoing or active infection (Viral, bacterial, fungal or other)

• Psychiatric illness/social situations that would limit compliance with study requirements

• Pregnant and breastfeeding women are excluded from this study. The effects of tegavivint on the developing human fetus have the potential for teratogenic or abortifacient effects. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with tegavivint

• Patients with abnormal serum chemistry values other than the specific limits detailed above, that in the opinion of the investigator is considered to be clinically significant, should be discussed with the Study PI before being enrolled in the study

• Personal history of malignancy except:

• Cervical intraepithelial neoplasia;

• Skin basal cell carcinoma;

• Treated localized prostate carcinoma with prostate specific antigen (PSA) <1 ng/mL or untreated indolent prostate cancer

• Neoplasia treated with curative intent, in remission for at least three years and considered at low risk of relapse

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Recurrence
• Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
• Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
• Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
• Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
• Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
• Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

Intervention

Procedure:
• Biospecimen Collection
Undergo blood sample collection
• Computed Tomography
Undergo CT
• Positron Emission Tomography
Undergo PET scan

Drug:
• Tegavivint
Given IV

Locations

Country	Name	City	State
United States	Ohio State University Comprehensive Cancer Center	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Lapo Alinari

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacokinetic (PK) analysis AUC0-t	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using AUC0-t	Up to 14 weeks
Other	Pharmacokinetic (PK) analysis AUC0-infinity	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using AUC0-infinity.	Up to 14 weeks
Other	Pharmacokinetic (PK) analysis Tmax	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using Tmax	Up to 14 weeks
Other	Pharmacokinetic (PK) analysis Cmax	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using Cmax.	Up to 14 weeks
Other	Pharmacokinetic (PK) analysis t1/2	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using t1/2.	Up to 14 weeks
Other	Pharmacokinetic (PK) analysis clearance	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using clearance.	Up to 14 weeks
Other	Pharmacokinetic (PK) analysis volume of distribution	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using volume of distribution.	Up to 14 weeks
Primary	Incidence of dose-limiting toxicity		At the end of Cycle 1 (each cycle is 28 days)
Primary	Maximum tolerated dose (MTD) for tegavivint	Determination of the MTD of tegavivint using a 3+3 design.	At the end of Cycle 1 (each cycle is 28 days)
Primary	Determination of the recommended phase II dose (RP2D) of tegavivint		At the end of Cycle 1 (each cycle is 28 days)
Secondary	Overall response rate (ORR)	Will be estimated by molecular subtype and across subtypes with exact 80% and 90% confidence intervals.	After cycle 2 (each cycle is 28 days) or end of treatment
Secondary	Complete response (CR) rate	Will be estimated by molecular subtype and across subtypes with exact 80% and 90% confidence intervals.	At the end of Cycle 2 (each cycle is 28 days)
Secondary	Duration of response (DOR)	Will be summarized by the Kaplan-Meier method, and two-year estimates will be provided with 80% and 90% confidence intervals, for each subtype and for all patients.	Time from the date of first response until the first date of progression or death from any cause, assessed up to 2 years from study enrollment
Secondary	Progression-free survival (PFS)	Will be summarized by the Kaplan-Meier method, and two-year estimates will be provided with 80% and 90% confidence intervals, for each subtype and for all patients.	Time from the date of first treatment until the first date of progression or death from any cause, assessed up to 2 years from study enrollment
Secondary	Event-free survival (EFS)	Will be summarized by the Kaplan-Meier method, and two-year estimates will be provided with 80% and 90% confidence intervals, for each subtype and for all patients.	Time from the date of first treatment until the first date of progression, re-treatment of lymphoma after initial immune-therapy, or death from any cause, assessed up to 2 years from study enrollment
Secondary	Overall survival (OS)	Will be summarized by the Kaplan-Meier method, and two-year estimates will be provided with 80% and 90% confidence intervals, for each subtype and for all patients.	Time from the date of first treatment until the date of death from any cause, assessed up to 2 years from study enrollment

External Links

•   The Jamesline